Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 70Neoplasm Metastasis 20Rectal Neoplasms 19Colonic Neoplasms 17Neoplasms 11Cholangiocarcinoma 7Carcinoma, Non-Small-Cell Lung 7Head and Neck Neoplasms 6Esophageal Neoplasms 6Breast Neoplasms 6Carcinoma, Squamous Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Colorectal Cancer Metastatic 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Carcinoma 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Fallopian Tube Neoplasms 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Serotonin Syndrome 1Salivary Gland Malignancy 1

Interventions

telotristat ethyl 3telotristat 1pasireotide 1lutetium Lu 177 dotatate 1alpha-methyltryptophan 1Random Allocation 1Panitumumab 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Serotonin Syndrome × Panitumumab × Clear all
NCT01172717 2013-07-26

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Boston Medical Center

Phase 2 Withdrawn
Endocrine

Carcinoid Tumor, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡